100% Same
Salt CompositionEffectivenessStrength
with Substitute Medicine
You Searched


WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)

WHO GMP
Certified

15 Days Easy
Returns

Long Expiry
(>8 Months)
Delivery by
Zerosita M 50mg 500mg Tablet Sr 10s is a fixed-dose combination medicine specifically designed for the effective management of Type 2 Diabetes Mellitus in adults. It combines Metformin and Sitagliptin to achieve superior blood sugar control. This dual-action treatment works synergistically by reducing glucose production in the liver and promoting insulin release after meals. By improving the body's response to insulin, Zerosita M 50mg 500mg Tablet Sr 10s helps lower high blood sugar levels, significantly reducing the long-term risk of serious complications such as kidney damage, nerve problems, and cardiovascular issues. This combination therapy is typically prescribed when diet, exercise, and single-drug therapy have not provided adequate glycemic control.
Zerosita M 50mg 500mg Tablet Sr 10s is a dual-action oral prescription therapy indicated for the long-term control of blood sugar in patients with Type 2 Diabetes Mellitus. The unique combination harnesses the power of two distinct drug classes to ensure sustained and comprehensive blood glucose reduction.
Metformin is the most widely used oral antidiabetic drug. It works primarily by decreasing the excessive glucose produced by the liver (hepatic glucose production) and improving the sensitivity of muscle and fat cells to insulin. This action allows the body to utilise its own insulin more effectively, helping to lower both fasting and post-meal glucose levels.
Sitagliptin belongs to the class of DPP-4 inhibitors. It functions by inhibiting the enzyme Dipeptidyl Peptidase-4 (DPP-4), which naturally breaks down incretin hormones (like GLP-1). By preserving these hormones, Sitagliptin enhances the pancreas's ability to release insulin (especially after meals when glucose is high) and further suppresses the liver's sugar production.
The synergistic effect of Metformin and Sitagliptin in Zerosita M 50mg 500mg Tablet Sr 10s often achieves a more sustained and consistent reduction in HbA1c (a measure of average blood sugar over 2-3 months) compared to monotherapy, leading to improved clinical outcomes for the patient. Consistent, once-daily or twice-daily usage, as directed by a healthcare professional, is essential. By helping to maintain blood sugar within the safe range, this medication not only supports vital organs but also dramatically lowers the lifetime risk of developing serious diabetes-related complications.
Metformin + Sitagliptin
The primary uses of Zerosita M 50mg 500mg Tablet Sr 10s (Metformin + Sitagliptin) are for the treatment and proactive management of Type 2 Diabetes Mellitus in adults:
The combination of Metformin and Sitagliptin provides a powerful, dual mechanism that targets different stages of glucose metabolism. This leads to a more comprehensive and sustained reduction in blood sugar compared to monotherapy, helping patients achieve their HbA1c goals more effectively.
The two components work together to manage glucose production and utilisation around the clock. Metformin primarily addresses basal (fasting) sugar levels by acting on the liver, while Sitagliptin enhances the body's natural insulin response after meals, ensuring control over post-prandial spikes.
Sitagliptin works in a glucose-dependent manner, meaning it only boosts insulin release when blood sugar is high. Because of this mechanism, Zerosita M 50mg 500mg Tablet Sr 10s carries a low intrinsic risk of causing dangerously low blood sugar (Hypoglycemia) when used on its own or just with Metformin.
Combining two necessary medications into a single tablet simplifies the patient's daily treatment regimen. This reduced pill burden generally improves patient adherence and makes long-term management of this chronic condition much easier.
While generally well-tolerated, Zerosita M 50mg 500mg Tablet Sr 10s may cause certain side effects. Most are mild and often subside as your body adjusts to the medication.
Disclaimer: If you experience any severe or persistent side effects, contact your healthcare provider immediately.
Always take Zerosita M 50mg 500mg Tablet Sr 10s strictly following your doctor's instructions regarding dosage, duration, and frequency.
Consultation Required. While controlled diabetes is essential, this combination is generally avoided during pregnancy, especially in the last trimester. Inform your doctor immediately if you are pregnant or planning to conceive; alternative treatment may be necessary.
Consultation Required. Both Metformin and Sitagliptin may pass into breast milk. A doctor must carefully weigh the therapeutic benefits for the mother against any potential risks to the nursing infant before recommending use.
AVOID. Alcohol significantly increases the risk of Lactic Acidosis (a rare, serious side effect of Metformin) and can also interfere with blood sugar regulation, leading to hypoglycemia or hyperglycemia.
Exercise Caution. The medicine itself has a low risk of causing hypoglycemia, but if combined with other diabetes drugs (like insulin or sulfonylureas), or if you experience dizziness, refrain from driving or operating heavy machinery until you understand how the medication affects you.
Caution Advised. Use requires close monitoring. Due to Metformin, this medicine is generally avoided or requires dose adjustment in moderate-to-severe kidney impairment. Liver function must also be regularly monitored.
Zerosita M 50mg 500mg Tablet Sr 10s is generally taken with food to minimise the gastrointestinal side effects associated with Metformin (e.g., nausea, diarrhoea). However, it is crucial to avoid excessive consumption of alcohol, as it drastically increases the risk of the severe metabolic complication, Lactic Acidosis.
It is essential to inform your doctor about all prescription drugs, over-the-counter medicines, vitamins, and herbal supplements you are currently taking, as Zerosita M 50mg 500mg Tablet Sr 10s can interact with several compounds:
Iodinated Contrast Agents: Taking Metformin must be temporarily stopped before and after receiving intravenous iodinated contrast agents (used in certain X-rays/scans) to prevent the immediate risk of acute kidney injury and Lactic Acidosis.
Carbonic Anhydrase Inhibitors (e.g., Topiramate, Zonisamide): These drugs can increase the risk of Lactic Acidosis when co-administered with Metformin.
Hyperglycemia-Causing Drugs: Medications such as corticosteroids (prednisone), thiazide diuretics, and atypical antipsychotics can cause hyperglycemia (high blood sugar), potentially reducing the effectiveness of Zerosita M 50mg 500mg Tablet Sr 10s. Dose adjustments may be necessary.
Other Diabetes Medications: Combining Zerosita M 50mg 500mg Tablet Sr 10s with other sugar-lowering drugs (e.g., Insulin, Sulfonylureas) may increase the risk of hypoglycemia, necessitating careful dose reduction of the co-administered drug.
Cimetidine: This drug can increase the concentration of Metformin in the blood.
Patients with certain underlying medical conditions must use Zerosita M 50mg 500mg Tablet Sr 10s with extreme caution and under close medical supervision:
If a dose of Zerosita M 50mg 500mg Tablet Sr 10s is missed, take it as soon as you remember, unless it is already almost time for your next scheduled dose. If the next dose is due soon (for instance, within a few hours for a twice-daily regimen), the missed dose should be skipped entirely, and you should continue with your regular dosing schedule. Never take two doses at once to compensate for a forgotten one, as this increases the risk of side effects, including gastrointestinal upset and, rarely, hypoglycemia.
https://www.mayoclinic.org/drugs-supplements/sitagliptin-and-metformin-oral-route/description/drg-20559685
https://www.drugs.com/mtm/metformin-and-sitagliptin.html
https://www.webmd.com/drugs/2/drug-148063-938/sitagliptin-metformin-oral/sitagliptin-metformin-oral/details
Therapeutic Class
Anti-diabetic agents / Type 2 Diabetes Management
Action Class
Hypoglycemic Agents (Oral Antidiabetics)
Chemical Class
Biguanide + Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Habit Forming
No
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Flat Rs 100 on first app order | Use Code: APP100 |
Flat Rs 100 on first app order
USE CODE: APP100

Download Now